Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,575 | -6,420 | -4,336 | -2,457 | -17,292 |
| Depreciation Amortization | 338 | 255 | 170 | 85 | 408 |
| Accounts payable and accrued liabilities | 233 | N/A | N/A | N/A | N/A |
| Other Working Capital | -423 | -1,301 | -2,003 | -557 | -175 |
| Other Operating Activity | 1,702 | 1,051 | 681 | 330 | 2,964 |
| Operating Cash Flow | $-7,726 | $-6,415 | $-5,488 | $-2,598 | $-14,094 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | N/A | 12 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $12 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 6,051 | 5,567 | 5,049 | 4,985 | N/A |
| Other Financing Activity | 1,623 | 1,643 | 1,644 | 1,674 | -1,343 |
| Financing Cash Flow | $7,674 | $7,210 | $6,693 | $6,658 | $-1,343 |
| Exchange Rate Effect | 5 | 28 | 9 | 8 | -10 |
| Beginning Cash Position | 2,288 | 2,288 | 2,288 | 2,288 | 17,724 |
| End Cash Position | 2,241 | 3,112 | 3,503 | 6,356 | 2,288 |
| Net Cash Flow | $-47 | $824 | $1,215 | $4,068 | $-15,436 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,726 | -6,415 | -5,488 | -2,598 | -14,094 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -5 |
| Free Cash Flow | -7,726 | -6,415 | -5,488 | -2,598 | -14,100 |